“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...

Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...

In the latest in a growing trend of pharma reshuffling moves in Asia, Marubeni Corporation is absorbing Sumitomo Pharma’s ...

Amid a dramatic reshaping of the federal healthcare apparatus, the FDA has named an acting leader of its Center for Biologics Evaluation and Research. | Amid a dramatic reshaping of the federal ...

Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

After a Houston judge denied Johnson & Johnson’s third attempt to resolve approximately 90,000 talcum powder lawsuits through ...

The talks between the administration and the industry, which have been taking place behind closed doors, have given some ...

Drug delivery specialist SHL Medical opened the doors to its new $220 million autoinjector production facility in South ...